Thesis, a NYC-based company that offers a customized approach to cognitive performance products based on their brain chemistry, closed on a Series A round totaling $8.4m.
Backers included Unilever Ventures, Redo Ventures, Alive VC, Break Trail, NBA superstar Kevin Love and model Kate Bock. Previously the company raised $5.1m in an undisclosed seed round that included Unilever Ventures, MBX, Trust Ventures and Redo Ventures.
The two rounds brought the total raised to date to over $13.5M.
The company intends to use the funds to expand out its product selection and clinical trials.
Led by Dan Freed, founder and CEO, Thesis offers potent nutrient compounds formulated to enhance mental performance, based on their unique brain chemistry and the cognitive states they want to achieve. Thesis offers specific blends and more to target specific outcomes whether taking the Energy Formula to overcome fatigue, the Clarity Formula to enter a flow state, or the Motivation Formula to decrease procrastination.
Thesis products are formulated with clinically studied active ingredients with the highest possible bioavailability and adhere to the FDA Current Good Manufacturing Processes (cGMP).
FinSMEs
02/05/2023